Sphera Funds Management’s Avalo Therapeutics AVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.6M Buy
234,968
+2,674
+1% +$49.2K 0.51% 66
2026
Q2
$4.29M Buy
+232,294
New +$3.67M 0.56% 61

Other funds holding AVTX

Sphera Funds Management's AVTX Position: Q3 2026 in Review

Sphera Funds Management increased its Avalo Therapeutics (AVTX) stake by 1.2% in Q3 2026, buying an estimated $49.2K and bringing the position to 234,968 shares worth $3.6M. The position accounts for 0.51% of the portfolio, ranked #66.

Sphera Funds Management first reported a position in AVTX in Q2 2026 and has held it in 2 quarters since. The position peaked at $4.29M in Q2 2026. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • Sphera Funds Management held 234,968 shares of Avalo Therapeutics worth $3.6M as of Q3 2026.
  • Sphera Funds Management bought 2,674 Avalo Therapeutics shares in Q3 2026, an estimated $49.2K.
  • Avalo Therapeutics made up 0.51% of Sphera Funds Management's portfolio in Q3 2026, its #66 holding.
  • Sphera Funds Management first reported a position in Avalo Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Sphera Funds Management's Avalo Therapeutics position peaked at $4.29M in Q2 2026.
  • 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on Sphera Funds Management's 13F filing for Q3 2026, filed 16 Nov 2026.